Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Electro-Optical bags $11.5m funding:

This article was originally published in Clinica

Executive Summary

Manufacturer of the MelaFind non invasive melanoma diagnosis tool Electro-Optical Sciences (Irvington, New York) has secured $11.5m in a private placement from institutional investors. The funding, invested by Cowen and Company and ThinkEquity Partners, comprised just over 2 million common shares priced at $5.75 per share and around 500,00 common stock warrants that are exercisable at $8.00 for 54 months beginning six months after the closing of the investment. The company will use the proceeds to further the design and development of MelaFind, which emits multiple wavelengths to capture images of suspicious pigmented skin lesions, and extract data which can be analysed to tell physicians whether or not a lesion should be biopsied.

You may also be interested in...

The Race Is On To Launch COVID-19 Antibody Home-Test In The UK

Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.

Russia May Cap Drug Prices In Fight Against COVID-19

As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products. 

European CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts